Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIB Study of the Efficacy and Safety of LIBERTAL, A Phosphatidic-Acid-Enriched Phospholipid, on Smoking Cessation

NCT00317213 is registered in ClinicalTrials.gov with Kaplan Medical Center as lead sponsor.

NCT NCT00317213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00317213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIB Study of the Efficacy and Safety of LIBERTAL, A Phosphatidic-Acid-Enriched Phospholipid, on Smoking Cessation
Lead sponsor
Kaplan Medical Center
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2002
Completion date
July 31, 2002
Enrollment
500
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

smoking